Johnson & Johnson defied generic competition to post positive Q3 figures, including increases to both turnover and worldwide pharmaceutical sales.
Turnover rose 6.8% to approximately $16bn, whereas worldwide pharmaceutical sales increase 8.9% to $5.98bn.
Go deeper with GlobalData
The company’s biggest earner continued to be anti-inflammatory Remicade, with sales witnessing a 14.6% increase to $1.41bn.
The detrimental effect of generic competition wasn’t completely unfelt, however, as group net earnings fell 6.3% to $3.2bn and US sales fell 6.1%, with domestic sales of antipsychotic medication Risperdal only totalling $8m.
J&J’s Topamax and Procrit / Eprex medications also suffered at the hands of generics, with sales falling by 7.9% and 5.7% respectively.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
